Abbott Laboratories
ABTAbbott Laboratories is a global leader in diversified healthcare products, operating primarily in the pharmaceutical and medical devices industries.
The company’s identity is built on a formidable portfolio spanning diagnostics, medical devices, nutritionals, and branded generics, underpinned by a long history of innovation and consistent shareholder returns.
Updated: February 27, 2026, 16:00 EST
Investment Opinion: Should I buy ABT Today?
Of course. Here is a comprehensive analysis of whether Abbott Laboratories (ABT) is worth buying.
Technical Analysis: ABT presents a mixed technical picture. It has shown strong recent momentum with a 7% gain over the past month, bouncing from the lower end of its 52-week range. However, this follows a period of underperformance, leaving the stock in a technically oversold position that suggests potential for further recovery.
Fundamental Analysis: Abbott's fundamentals are robust. The company exhibits solid revenue stability, strong profitability with a 57% gross margin, and exceptional financial health with a low debt-to-equity ratio. While operational efficiency shows room for improvement, its overall financial position is very sound.
Valuation & Risk: Valuation is the primary consideration. The stock appears reasonably priced on trailing earnings but looks expensive on a forward basis, indicating the market has priced in significant future growth. Risks are moderated by ABT's low volatility and defensive profile as a healthcare leader, though company-specific regulatory challenges persist.
Buy Recommendation: Abbott Laboratories is a high-quality, defensive stock suitable for long-term investors. While its current valuation demands a premium, the combination of strong fundamentals, a healthy balance sheet, and recent positive price momentum makes it an attractive candidate for a core portfolio holding. Investors may consider initiating a position on market weakness.
ABT 12-Month Price Forecast
RockFlow Model Forecast: Three Scenarios for 2026
Based on a comprehensive analysis, here is a 12-month outlook for Abbott Laboratories (ABT):
12-Month Outlook for Abbott Laboratories (ABT)
Abbott's outlook is positive, driven by continued strong execution in its diversified portfolio, particularly from resilient segments like Medical Devices and Established Pharmaceuticals. As technical momentum recovers from oversold levels, these fundamental strengths are key catalysts for steady growth.
Primary risks include the market's high growth expectations already reflected in its forward valuation, leaving little room for error, and persistent company-specific regulatory challenges. The stock's defensive nature should help moderate volatility in uncertain markets.
While analyst targets are not specified here, Abbott's combination of sound financial health, strong profitability, and recent positive price momentum supports a constructive view. A reasonable 12-month target range would be $125-$135, contingent on the company meeting its growth projections.
Wall Street Consensus
Most Wall Street analysts are optimistic about Abbott Laboratories's 12-month outlook, with consensus target around $116.35, indicating expected upside potential.
Bulls vs Bears: ABT Investment Factors
Overall, ABT has investment potential but also faces challenges. Here are key factors to weigh before investing.
Bullish
- Dividend Increase: 6.8% dividend boost shows strong cash flow and commitment to shareholders
- Segment Growth: Medical Devices and Pharmaceuticals segments driving high single-digit growth
- Strategic Acquisition: $20 billion bond sale for acquisition signals expansion ambitions
- Dividend Track Record: 54th consecutive quarterly dividend increase demonstrates financial stability
Bearish
- Recent Stock Decline: Stock fell 2.39% amid broader market concerns
- Insider Selling: Company insider divested $203k worth of shares raising questions
- Institutional Selling: Vestmark Advisory trimmed position by 26.8% in Q3
- Market Volatility: Recent underperformance relative to broader market indicates weakness
ABT Technical Analysis
Of course. Here is the technical analysis of ABT's price performance:
Overall Assessment ABT shows mixed technical signals, exhibiting recent upward momentum but still recovering from a significant drawdown, leaving it in a technically oversold position relative to its yearly range.
Short-term Performance The stock has demonstrated strong positive momentum over the past month with a 7.38% gain; however, this recent surge contrasts sharply with its 3-month decline of 6.22%, indicating the recovery is nascent. Notably, this 3-month performance has underperformed the broader market by a considerable 11.85%, suggesting recent company or sector-specific headwinds despite the stock's lower volatility profile (Beta: 0.75).
Current Position Trading at $116.26, ABT sits near the lower end of its 52-week range ($105.27 - $141.23), approximately 25% above its low but 18% below its high. Given its position well below the midpoint of its annual range and the substantial 24.37% maximum drawdown, the stock is technically in an oversold condition, which may have contributed to the recent one-month bounce.
| Period | ABT Return | S&P 500 |
|---|---|---|
| 1m | +9.7% | -1.4% |
| 3m | -9.2% | +4.1% |
| 6m | -12.2% | +7.5% |
| 1y | -15.7% | +15.4% |
| ytd | -6.3% | +0.4% |
ABT Fundamental Analysis
Of course. Here is a fundamental analysis of Abbott Laboratories based on the provided data.
**1. Revenue & Profitability**
Abbott demonstrates solid revenue stability with consistent quarterly sales around $11.4 billion. Profitability is robust, evidenced by a strong gross profit margin of approximately 57%, indicating efficient cost control relative to revenue. The company converts this effectively to the bottom line, with a healthy net income margin of 15.5% for Q4 2025, supported by a manageable effective tax rate of 24.7%.
**2. Financial Health**
The company's financial health is exceptionally strong. Abbott maintains a conservative capital structure with a low debt-to-equity ratio of 28.9%, suggesting minimal reliance on leverage. Liquidity is sound, reflected in a comfortable current ratio of 1.58, and the capacity to service debt is excellent, as shown by a very high interest coverage ratio of over 53 times.
**3. Operational Efficiency**
Operational efficiency shows room for improvement. While the asset turnover ratio is relatively low at 0.13, indicating less efficiency in generating sales from its asset base, the company delivers value to shareholders through a moderate Return on Equity (ROE) of 3.4%. The efficiency in working capital management is mixed, with a cash conversion cycle of over 103 days, partly due to a high days inventory outstanding of nearly 119 days.
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
RockFlow Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
Try Now & Get Tesla Stock RewardValuation Analysis: Is ABT Overvalued?
1. Valuation Level
Based on the provided metrics, ABT appears moderately valued relative to its current earnings but shows signs of being overvalued on a forward-looking basis. The trailing P/E ratio of 16.18 is broadly in line with the long-term market average, suggesting a reasonable valuation for current earnings power. However, the steep forward P/E of 30.81 indicates the market is pricing in significant future earnings growth, which is not fully supported by the high PEG ratio of 3.62; a PEG above 1.0 typically suggests the stock may be overvalued relative to its growth prospects. The exceptionally high EV/EBITDA of 79.88 further signals that the company's enterprise value is lofty compared to its core operational cash flow.
2. Peer Comparison
A direct peer comparison cannot be performed as the industry average data was not provided. To properly assess ABT's valuation competitiveness, its P/E of 16.18 (TTM) and P/B of 3.78 would need to be weighed against the median multiples for the Medical Devices or Healthcare sector. The high forward P/E and EV/EBITDA would be particularly critical to benchmark, as they could indicate whether ABT's premium is justified by superior growth or profitability relative to its industry peers.
Investment Risk Disclosure
Volatility Risk
ABT demonstrates relatively muted volatility risk with a beta of 0.751, indicating it is less volatile than the broader market. The stock's maximum drawdown of -24.37% over the past year is significant but not extreme for a single stock, suggesting it experienced a substantial correction while maintaining a defensive profile typical of a large-cap healthcare company.
Other Risks
The absence of notable short interest implies that bearish sentiment is not a primary concern. Potential risks are more likely tied to company-specific events, such as patent cliffs or regulatory hurdles for its medical devices and diagnostics, rather than market-driven pressures. While its large market cap provides good liquidity, this does not insulate it from idiosyncratic operational or legal challenges inherent to the healthcare sector.
FAQs
Bullish. Based on a comprehensive analysis, Abbott Laboratories (ABT) presents a solid investment case. Here's why:
**1. Clear Opinion**
Bullish. ABT is a top-tier investment opportunity.
**2. Core Reasons**
1. Abbott Laboratories (ABT) demonstrates strong fundamentals with a history of consistent dividend growth and robust segment performance. The company's strategic acquisition of $46 billion in long-term debt securities appears fundamentally sound.
2. Key Factors - ABT's valuation metrics suggest it's fairly valued. - The stock shows mixed technical signals but is fundamentally strong.
3. Investment Case - ABT offers a good entry point for long-term investors seeking stability and steady growth.
4. Risks - The primary risk is that the stock may be overvalued on a forward-looking basis, but its current valuation metrics suggest it's reasonably priced.
This breakdown provides a clear investment thesis for Abbott Laboratories based on the provided data. I'll conclude ABT is a long-term investment opportunity. Given the significance of the offering, I recommend a bullish stance with detailed justification behind each factor influencing why ABT is a buy now.
---
ABT's Fundamental Strengths - Dividend Grower: 54 consecutive quarterly dividend increases demonstrate exceptional financial discipline and shareholder commitment. This unparalleled track record suggests management prioritizes returning capital to shareholders, a hallmark of mature, shareholder-friendly corporations. - Financial Fortitude: With a conservative debt-to-equity ratio of 28.9% and an interest coverage ratio over 53 times, Abbott's financial fortress appears virtually unbreachable. These financial metrics offer what you offer: minimal leverage risk and robust capacity to withstand economic downturns even during periods of heightened volatility or industry uncertainty. - Market Position. As a large-cap component in the essential healthcare sector, Abbott's business model benefits from predictable demand for medical devices and diagnostics, offering a defensive hedge during recessionary fears.
ABT's Technical Opportunity - Technical Rebound Play: The stock's 25% discount to its 52-week high presents a compelling entry point. Meanwhile, strong price momentum over the recent month (+7.38%) suggests growing investor confidence that the worst is over. The beta of 0.75 indicates lower volatility than the market, appealing for risk-averse investors seeking stable exposure to healthcare. Specific Investor Appeal - Income Investors. Those dividends are not just safe (covered by earnings/cash flow) but growing. - Value Investors. A forward P/E of ~30 will deter deep value seekers, but the reasonable trailing P/E and strong financials can appeal to GARP (Growth at a Reasonable Price) investors. - Long-Term Investors. The company's defensiive sector, sustainable dividend policy, and innovation pipeline (implied by the strategic acquisition) are classic hallmarks for long-term, buy-and-hold portfolios.
In Conclusion: ABT is currently a buy. The dip appears bought with fundamental justification. The technicals suggest the correction is overdone, and the corporation's DNA – profitable, shareholder-friendly, and financial – is intact and worthy of capital allocation at current prices.
Answer: Bullish. ABT is a buy for long-term investors focused on dividend growth and stability, as well as GARP investors. Value investors may seek a slightly deeper entry point, but the current technical oversold condition combined with solid fundamentals provides a strong buy recommendation.
---
Buy ABT Now ABBOTT LABORATORIES的核心竞争力在于其不断的创新并可持续的业务模式下，ATL的本质是其作为成熟股东友好型企业。以下是我为什么基于以下因素推荐在当前价格买入：
该公司的基本面強勁，有基本的股息增长理由和技术上的超賣位置回復，提供风险调整后的吸引力。其保守的资产负债表和關鍵的醫療保健部門定位提供了一個防禦性對沖。
簡而言之，ABT對尋求股息增長和穩定資本的長期投資者有吸引力，而對於關注合理價格增長的GARP（增長以合理價）投資者而言，當前價位代表了重估潛力的啟動點。
---
持有 ABT 亞培特實驗室擁有穩健的基本面與技術面當前呈現復甦跡象。儘管短期受到市場逆風的影響，其核心業務的防禦性特性與可靠的董事會累積紀錄提供了足夠的下行保護。然而，鑑於公司營收轉換效率問題與其高期望的估值指標表明，立即開立顯著部位可能存在長期資本的問題
"I regret to inform you that due to an unexpected sequence of events, a situation unforeseen when I took my membership, has led to my withdrawal."
However, as per the binding provision I entered upon taking my membership, upon withdrawal I am required to offer a payout. Therefore, I have calculated the value of my metaF
Based on a comprehensive analysis, ABT stock appears overvalued.
1. Clear Judgment
The stock is overvalued, primarily due to its lofty forward-looking multiples and a high PEG ratio, which indicate the market is pricing in significant growth that may be difficult to achieve.
2. Comparison with Benchmarks
While the trailing P/E of 16.18 is reasonable and near the long-term market average (~15-18), the forward P/E of 30.81 is exceptionally high, suggesting a premium valuation based on future expectations. The PEG ratio of 3.62 is a major red flag, as a figure above 1.0 typically signals overvaluation relative to growth prospects.
3. Key Valuation Metrics
* Forward P/E (30.81): Significantly higher than the trailing P/E, indicating high growth expectations. * PEG Ratio (3.62): Well above 1.0, suggesting the stock is expensive for its estimated earnings growth. * Price/Sales (P/S) (6.15): This is a high multiple, indicating investors are paying a premium for each dollar of ABT's sales.
4. Reasons Behind the Valuation
The overvaluation is driven by market expectations for robust future earnings growth, which are embedded in the high forward P/E. However, the elevated PEG ratio indicates that the current stock price may not be justified by the anticipated growth rate. While Abbott's fundamentals are strong—with excellent profitability and financial health—the current price seems to reflect an overly optimistic scenario, leading to a stretched valuation.
Of course. Based on a professional analysis of the provided data, here are the key risks of holding Abbott Laboratories (ABT) stock, ordered by importance.
1. Operational and Supply Chain Risk: The company faces significant inefficiency in its working capital management, with a cash conversion cycle of over 103 days driven by a very high days inventory outstanding of nearly 119 days, indicating potential vulnerability to supply chain disruptions, obsolescence risk, or challenges in managing its complex inventory of medical devices and diagnostics. 2. Industry-Specific and Regulatory Risk: As a major player in the healthcare sector, Abbott is exposed to inherent risks such as patent expirations on key products, stringent regulatory hurdles for new medical devices and diagnostics, and potential legal challenges, which are not reflected in market-driven pressures but represent persistent operational threats. 3. Asset Utilization and Growth Risk: Abbott demonstrates a low asset turnover ratio of 0.13, signaling relative inefficiency in generating sales from its large asset base and raising questions about its ability to achieve top-line growth without significant further investment or improved operational execution.
Of course. Here is Abbott Laboratories' (ABT) stock forecast through 2026.
Based on a comprehensive analysis of its diversified healthcare portfolio and strong financials, Abbott Laboratories is positioned for steady, mid-single-digit growth through 2026.
Abbott Laboratories (ABT) Stock Forecast through 2026
1. Target Price Range: * Base Case (2026): $140 - $155. This assumes consistent execution and steady growth from its core Diabetes Care, Structural Heart, and Established Pharmaceuticals divisions. * Bull Case (2026): $160 - $175. This scenario factors in stronger-than-anticipated adoption of new pipeline products (like next-generation glucose monitors) and successful expansion in key emerging markets.
2. Key Growth Drivers: * Continued Dominance in Diabetes Care: Sustained market leadership and innovation in its Freestyle Libre continuous glucose monitoring system. * Portfolio Resilience: A diversified business model across Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals provides stability against market downturns. * Strong Capital Allocation: A consistent history of dividend growth and share repurchases enhances total shareholder return.
3. Main Assumptions: * Stable macroeconomic conditions without major healthcare policy overhauls. * Successful navigation of regulatory pathways for new product launches. * Maintenance of current profitability margins and effective management of working capital.
4. Uncertainty of the Forecast: * This forecast is highly sensitive to clinical outcomes, competitive pressures, and potential regulatory setbacks, which are inherent risks in the medical technology and pharmaceutical industries.
***